Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats.
Neurosci Lett
; 648: 41-46, 2017 05 01.
Article
en En
| MEDLINE
| ID: mdl-28363754
ABSTRACT
One main pathological hallmark of multiple sclerosis (MS) is demyelination. Novel therapies which enhance myelin repair are urgently needed. Insulin and insulin-like growth factor 1 (IGF-1) have strong functional relationships. Here, we addressed the potential capacity of IGF-1 and insulin to enhance remyelination in an animal demyelination model in vivo. We found that chronic intrathecal infusion of IGF-1 enhanced remyelination after lysolecithin-induced demyelination in the spinal cord of young and aged rats. Aged rats showed a weaker innate remyelination capacity and are therefore a good model for progressive MS which is defined by chronic demyelination. In contrast to IGF-1, Insulin had no effect on remyelination in either age group. Our findings highlight the potential use of IGF-1 as remyelinating therapy for MS, particularly the progressive stage in which chronic demyelination is the hallmark.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Factor I del Crecimiento Similar a la Insulina
/
Enfermedades Desmielinizantes
/
Insulina
/
Vaina de Mielina
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Neurosci Lett
Año:
2017
Tipo del documento:
Article
País de afiliación:
Suiza